Clinical trials: Major Depressive Disorder
Depressive Disorder, Major
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake…
- Trial name
- ESCAPE-TRD (NCT04338321)
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Where
- 171 sites in Argentina, Austria and 22 more
- Volunteers
- 676 people
- Sponsor
- Janssen-Cilag International NV
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01153347
- Testing
- TC-5214
- Where
- 99 sites in United States, India and 1 more
- Volunteers
- 2,409 people
- Sponsor
- AstraZeneca
Major Depression, Generalized Anxiety Disorder
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
The hypothesis of this study is that symptoms of anxiety, depression and insomnia; and indices of psychosocial function will all improve, while BZ use will decrease significantly during a twelve-week trial period of substituting…
- Trial name
- NCT01244711
- Testing
- quetiapine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder, Dysthymia
Project to Improve Symptoms and Mood in People With Spinal Cord Injury
Depression is likely the most prevalent and disabling psychological complication associated with spinal cord injury (SCI). Yet no controlled depression treatment trials have been performed in this population.
- Conditions
- Major Depressive Disorder, Dysthymia, Spinal Cord Injuries
- Trial name
- PRISMS (NCT00592384)
- Testing
- venlafaxine XR
- Where
- 6 sites in United States
- Volunteers
- 133 people
- Sponsor
- University of Washington
Depressive Disorder
Study Of 323U66 SR In Major Depressive Disorder
This study was designed to evaluate the efficacy and safety in major depressive disorder patients.
- Trial name
- NCT00135512
- Testing
- bupropion hydrochloride
- Where
- 7 sites in Japan
- Volunteers
- 234 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
An outpatient study to evaluate the safety and efficacy of cariprazine as adjunct to antidepressant therapy (ADT) in participants with major depressive disorder (MDD) who have an inadequate response to ADT alone.
- Trial name
- NCT01469377
- Testing
- Cariprazine
- Where
- 72 sites in United States, Estonia and 4 more
- Volunteers
- 819 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Major
A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression
This is a home-based study in adults with depression. People who have been diagnosed with Major Depressive Disorder can participate in the study.
- Trial name
- NCT04423757
- Testing
- BI 1358894
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Depression, Unipolar
Treating Major Depression With Yoga: A Prospective, Randomized Controlled Pilot Trial
This was a randomized controlled pilot trial to evaluate clinical efficacy and feasibility of hatha yoga as a mono-therapy for major depression.
- Trial name
- NCT01210651
- Testing
- Hatha Yoga Practice Group, Attention Control Education Group
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of California, San Francisco
Depression
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major…
- Trial name
- NCT01305408
- Testing
- Armodafinil
- Where
- 130 sites in United States, Argentina and 12 more
- Volunteers
- 399 people
- Sponsor
- Cephalon
Major Depressive Disorder
A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients
The purpose of this study is to compare the efficacy and safety of duloxetine 60 mg once daily to placebo on depression in elderly patients (greater than or equal to 65 years of age).
- Trial name
- NCT00406848
- Testing
- duloxetine hydrochloride
- Where
- 33 sites in United States, France and 2 more
- Volunteers
- 370 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work.
- Trial name
- NCT06280235
- Testing
- BI 1569912
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 243 people
- Sponsor
- Boehringer Ingelheim
Depression, Major Depressive Disorder
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
The purposes of this project are to examine the feasibility, safety, tolerability and clinical effect of low-dose buprenorphine as a novel treatment for late-life treatment-resistant depression and to develop preliminary data…
- Trial name
- IRLGREY-B (NCT02176291)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Jordan F. Karp
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder.
- Trial name
- NCT00969150
- Testing
- Levomilnacipran ER
- Where
- 25 sites in United States
- Volunteers
- 362 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Major, Cannabis Abuse
Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
Adolescents who are diagnosed with major depressive disorder are often also diagnosed with marijuana dependence. Fluoxetine is an antidepressant medication currently used to treat young people who are diagnosed with major…
- Trial name
- CADY (NCT00149643)
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Pittsburgh
Bipolar Depression
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major…
- Trial name
- NCT03249376
- Testing
- Lumateperone
- Where
- 47 sites in United States, Bulgaria and 4 more
- Volunteers
- 381 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depression
The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
Participating subjects are those who are referred for electroconvulsive therapy (ECT) for severe depression who have agreed to the protocol. The control group receives ECT as usual.
- Trial name
- NCT00616759
- Testing
- electroconvulsive therapy, electroconvulsive therapy plus propofol, propofol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Loma Linda University
Major Depressive Disorder
A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term…
- Trial name
- NCT03538691
- Testing
- Brexpiprazole, Antidepressant therapy
- Where
- United States
- Volunteers
- 1,149 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Unipolar Depression, Bipolar Depression
The Antidepressant Efficacy of the Anticholinergic Scopolamine
A previous study showed that the intravenous administration of scopolamine produces antidepressant effects. This study is designed to determine if other routes of administration of scopolamine produce antidepressant effects.
- Trial name
- NCT00369915
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02158546
- Testing
- ALKS 5461
- Where
- 58 sites in United States, Bulgaria
- Volunteers
- 447 people
- Sponsor
- Alkermes, Inc.
Major Depressive Disorder With Psychotic Features
Study of Pharmacotherapy of Psychotic Depression
This study will determine the effectiveness of combining selective serotonin reuptake inhibitors (SSRIs) with antipsychotic medications in the treatment of psychotic depression.
- Trial name
- STOP-PD (NCT00056472)
- Testing
- Olanzapine, Sertraline
- Where
- 4 sites in United States, Canada
- Volunteers
- 259 people
- Sponsor
- Weill Medical College of Cornell University